Shrier Wealth Management LLC Makes New Investment in Abbott Laboratories $ABT

Shrier Wealth Management LLC bought a new stake in Abbott Laboratories (NYSE:ABT) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 20,751 shares of the healthcare product maker’s stock, valued at approximately $2,600,000. Abbott Laboratories makes up approximately 1.0% of Shrier Wealth Management LLC’s investment portfolio, making the stock its 28th largest position.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Cloud Capital Management LLC purchased a new stake in Abbott Laboratories in the 3rd quarter worth about $29,000. Guerra Advisors Inc acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at about $31,000. Delos Wealth Advisors LLC acquired a new position in shares of Abbott Laboratories in the 2nd quarter valued at about $32,000. Bridge Generations Wealth Management LLC purchased a new stake in shares of Abbott Laboratories in the third quarter worth approximately $33,000. Finally, Copia Wealth Management acquired a new stake in shares of Abbott Laboratories during the third quarter worth approximately $38,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ABT. Royal Bank Of Canada dropped their price objective on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Sanford C. Bernstein lowered their price target on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. The Goldman Sachs Group dropped their price target on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. BTIG Research reduced their price objective on Abbott Laboratories from $140.00 to $131.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Oppenheimer lowered their target price on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $135.68.

Abbott Laboratories Stock Up 0.7%

Abbott Laboratories stock opened at $102.59 on Wednesday. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a 1-year low of $100.88 and a 1-year high of $139.06. The firm’s fifty day simple moving average is $110.05 and its 200-day simple moving average is $121.57. The company has a market capitalization of $178.68 billion, a P/E ratio of 27.58, a P/E/G ratio of 1.63 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. Abbott Laboratories’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Insiders Place Their Bets

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares in the company, valued at $16,918,253.66. This trade represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Eric Shroff sold 709 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the sale, the senior vice president owned 39,164 shares of the company’s stock, valued at $4,526,575.12. The trade was a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,055 shares of company stock worth $353,097 in the last three months. 0.46% of the stock is owned by insiders.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Precision Oncology tests are now integrated into Flatiron Health’s OncoEMR, giving more than 1,600 community cancer centers and ~4,700 providers the ability to order and receive Abbott test results inside their clinical workflow — a direct adoption catalyst for tests such as Oncotype DX, OncoExTra and Oncodetect that can lift diagnostics volume and recurring revenue. Abbott expands access to Precision Oncology
• Positive Sentiment: Abbott is a strategic investor in Whoop’s $575M Series G round (company valued at ~$10.1B). That stake gives Abbott optionality in wearable/consumer biometric data and potential commercial partnerships as Whoop scales globally and eyes an IPO — a complementary play to Abbott’s diabetes and consumer health franchises. Whoop raises $575M, adds Abbott as strategic investor
• Positive Sentiment: Industry research flags the global medical nutrition market growing to ~$31.1B by 2035, with Abbott named among key innovators — a favorable long-term demand backdrop for Abbott’s Nutrition segment once it stabilizes. Global Medical Nutrition Market to Reach USD 31.1 Billion by 2035
• Neutral Sentiment: Analyst note: BTIG trimmed its price target from $140 to $131 but maintained a Buy rating — a modest near-term view change but still a constructive stance implying upside from current levels. BTIG lowers ABT price target
• Neutral Sentiment: Recent analyst and media coverage highlights a mixed fundamental picture: Nutrition sales have pressured near-term growth, but Medical Devices (including FreeStyle Libre CGM and structural heart/electrophysiology businesses) remain strong; management is executing turnaround plans and pursuing the Exact Sciences acquisition — important long-term catalysts but with near-term execution risk. A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
• Negative Sentiment: Price action & volatility: recent trading showed a pullback to near 52‑week lows amid sector rotation and nutrition weakness, which has pressured sentiment even though core businesses remain solid. Short-term selling and investor rotation remain risks. Abbott (ABT) Dips More Than Broader Market

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.